Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors

<p>Abstract</p> <p>Splenomegaly is a common sign of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), and post-essential thrombocythemia myelofibrosis (post-ET MF) that is associated with bothersome symptoms, which have a significant negative impact on...

Full description

Bibliographic Details

Published in:	Journal of Hematology & Oncology
Main Authors:	Randhawa Jasleen, Ostojic Alen, Vrhovac Radovan, Atallah Ehab, Verstovsek Srdan
Format:	Article
Language:	English
Published:	BMC 2012-08-01
Subjects:	JAK2 inhibitor Myeloproliferative neoplasms Myelofibrosis JAK2V617F mutation Splenomegaly
Online Access:	http://www.jhoonline.org/content/5/1/43